SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
The Gariep Dam overflowing. The dam is the largest in South Africa. It is in the Orange River on the border between the Free State and Eastern Cape Provinces. Monochrome
Deals
Biopharma Deals Start Flowing at JPM25—With One Dwarfing Last Year’s Activity
J.P. Morgan kicked off with a flurry of deals, with Eli Lilly, GSK and Gilead all announcing deals potentially worth more than $1 billion while J&J committed $14.6 billion to buy Intra-Cellular. These moves have reinvigorated sentiment across the biopharma industry.
January 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Drug Development
Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.
January 14, 2025
 · 
1 min read
 · 
Kate Goodwin
Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
 · 
2 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Cancer
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow conversion of patients to the high-dose formulation.
January 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
GLP-1
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward.
January 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Earnings
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO Capital Markets analysts.
January 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway
Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.
January 13, 2025
 · 
1 min read
 · 
Angela Gabriel
3D illustration of an antibody-drug conjugate
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS